ASSERTIO HOLDINGS INC (ASRT)
US04546C2052 - Common Stock
Taking everything into account, ASRT scores 3 out of 10 in our fundamental rating. ASRT was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ASRT is average, but there are quite some concerns on its profitability. ASRT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ASRT has reported negative net income.
ASRT had a positive operating cash flow in the past year.
In the past 5 years ASRT reported 4 times negative net income.
ASRT had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ASRT (-115.87%) is worse than 85.64% of its industry peers.
ASRT has a Return On Equity of -240.49%. This is in the lower half of the industry: ASRT underperforms 76.92% of its industry peers.
ASRT's Return On Invested Capital of 6.63% is amongst the best of the industry. ASRT outperforms 86.15% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ASRT is significantly below the industry average of 16.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.87% | ||
| ROE | -240.49% | ||
| ROIC | 6.63% |
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)8.58%
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 10.66%, ASRT belongs to the top of the industry, outperforming 84.62% of the companies in the same industry.
In the last couple of years the Operating Margin of ASRT has declined.
ASRT has a Gross Margin of 82.36%. This is amongst the best in the industry. ASRT outperforms 84.62% of its industry peers.
ASRT's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.66% | ||
| PM (TTM) | N/A | ||
| GM | 82.36% |
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
2. Health
2.1 Basic Checks
ASRT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ASRT has been increased compared to 1 year ago.
The number of shares outstanding for ASRT has been increased compared to 5 years ago.
The debt/assets ratio for ASRT has been reduced compared to a year ago.
2.2 Solvency
ASRT has an Altman-Z score of -1.81. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
ASRT's Altman-Z score of -1.81 is in line compared to the rest of the industry. ASRT outperforms 46.67% of its industry peers.
The Debt to FCF ratio of ASRT is 0.79, which is an excellent value as it means it would take ASRT, only 0.79 years of fcf income to pay off all of its debts.
ASRT's Debt to FCF ratio of 0.79 is amongst the best of the industry. ASRT outperforms 95.90% of its industry peers.
ASRT has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
ASRT has a Debt to Equity ratio (0.28) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.79 | ||
| Altman-Z | -1.81 |
ROIC/WACC0.79
WACC8.35%
2.3 Liquidity
A Current Ratio of 1.83 indicates that ASRT should not have too much problems paying its short term obligations.
ASRT has a Current ratio of 1.83. This is in the lower half of the industry: ASRT underperforms 68.72% of its industry peers.
ASRT has a Quick Ratio of 1.43. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.43, ASRT is doing worse than 69.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.43 |
3. Growth
3.1 Past
ASRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.74%.
Looking at the last year, ASRT shows a decrease in Revenue. The Revenue has decreased by -2.63% in the last year.
Measured over the past years, ASRT shows a very negative growth in Revenue. The Revenue has been decreasing by -13.38% on average per year.
EPS 1Y (TTM)-156.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-145.52%
Revenue 1Y (TTM)-2.63%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Revenue growth Q2Q-34.55%
3.2 Future
Based on estimates for the next years, ASRT will show a very strong growth in Earnings Per Share. The EPS will grow by 41.60% on average per year.
The Revenue is expected to decrease by -7.76% on average over the next years.
EPS Next Y87.88%
EPS Next 2Y41.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-23.25%
Revenue Next 2Y-7.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ASRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ASRT is valued cheaper than 98.46% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASRT indicates a rather cheap valuation: ASRT is cheaper than 99.49% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.69 | ||
| EV/EBITDA | 1.06 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASRT's earnings are expected to grow with 41.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.6%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ASRT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASSERTIO HOLDINGS INC
NASDAQ:ASRT (4/24/2024, 7:00:01 PM)
After market: 0.87 +0 (+0.51%)0.8656
-0.04 (-4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap82.23M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.87% | ||
| ROE | -240.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.66% | ||
| PM (TTM) | N/A | ||
| GM | 82.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-156.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y87.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.63%
Revenue growth 3Y12.68%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y